Ultragenyx's Angelman syndrome drug fails Phase 3 trial

Ultragenyx Pharmaceutical's experimental Angelman syndrome drug apazunersen failed its Phase 3 Aspire trial, showing no efficacy difference compared to a sham control. The setback caused Ultragenyx's stock to lose nearly half its value, forcing the company to plan significant cost cuts and corporate restructuring. The failure also shifts pressure to competitors Ionis Pharmaceuticals and Oak Hill Bio, who are developing similar paternal UBE3A-activating antisense therapies.

Apazunersen Phase 3 trial failure

• ▪The Phase 3 Aspire study enrolled 129 patients aged 4 to 17 with a genetically confirmed deletion of maternal UBE3A, comparing apazunersen to a sham procedure over 338 days
• ▪Ultragenyx Pharmaceutical's experimental Angelman syndrome drug apazunersen, also known as GTX-102, failed to meet its primary and key secondary endpoints in the Phase 3 Aspire study
• ▪Leerink Partners analyst Joseph Schwartz suggested that the positive gains observed in the Phase 2 trial of apazunersen may have been due to natural developmental progression, practice effects, and expectation bias
• ▪Ultragenyx Pharmaceutical reported that there were no differences in efficacy between the treated and control groups in the Phase 3 Aspire study of apazunersen

Antisense UBE3A activation mechanism

• ▪Apazunersen is an antisense oligonucleotide designed to inhibit the long non-coding RNA that silences the paternal UBE3A gene, aiming to activate the gene to produce a key nervous system enzyme
• ▪Ultragenyx Pharmaceutical acquired the apazunersen program, originally named GTX-102, by purchasing GeneTx Biotherapeutics in 2022 for $91.2 million upfront following a 2019 collaboration

Ultragenyx restructuring plans

• ▪Ultragenyx Pharmaceutical faces a September 19, 2026, FDA decision date for UX111, a gene therapy for Sanfilippo syndrome type A with estimated peak sales of $120 million to $240 million
• ▪Following the Phase 3 trial failure of apazunersen, Ultragenyx Pharmaceutical announced plans for a corporate restructuring and forecasted significant expense reductions to focus on approved products and reach profitability by 2027
• ▪Ultragenyx Pharmaceutical reported $673 million in total revenue for 2025 from four commercialized products and recently received FDA approval in August 2026 for Genglycos, a gene therapy for glycogen storage disease type Ia
• ▪Ultragenyx Pharmaceutical's stock lost almost half of its value on September 3, 2026, following the announcement of the apazunersen Phase 3 trial failure

Ionis Oak Hill competitor programs

• ▪Ionis Pharmaceuticals is developing obudanersen, a paternal UBE3A-activating antisense drug candidate for Angelman syndrome, with Phase 3 data expected in 2027
• ▪Analysts suggest that competitor drugs from Ionis Pharmaceuticals and Oak Hill Bio may still succeed if they offer higher doses or superior potency compared to Ultragenyx's apazunersen
• ▪Oak Hill Bio is preparing to advance rugonersen, an Angelman syndrome candidate acquired from Roche, into pivotal testing supported by capital from a SPAC merger on track to close by the end of 2026

Angelman syndrome treatment development

• ▪Angelman syndrome is a rare neurogenetic disorder caused by the loss of function of the maternal UBE3A gene, resulting in developmental and movement issues, with no FDA-approved treatments currently available
• ▪A separate Phase 3 trial is evaluating apazunersen in rarer Angelman genotypes, though William Blair analyst Sami Corwin noted commercialization would be challenging due to the small patient population

2 sources